Menstrual status at baseline | | | |
Postmenopausal, n = 79 | −2.31 ± 5.10 | −1.40 ± 4.58 | −0.55 ± 6.84 |
Premenopausal, n = 46 | −2.57 ± 6.38 | −2.00 ± 5.91 | −0.74 ± 8.15 |
p | 0.801 | 0.553 | 0.893 |
Transitional menstrual status during followup | | | |
Yes, n = 16 | −5.80 ± 6.13 | −5.26 ± 5.23 | −5.38 ± 6.06 |
No, n = 109 | −1.89 ± 5.36 | −1.08 ± 4.88 | 0.08 ± 7.24 |
p | 0.009* | 0.002* | 0.005* |
Flare during followup | | | |
Yes, n = 44 | −3.48 ± 5.47 | −3.44 ± 4.75 | −3.10 ± 6.35 |
No, n = 81 | −1.80 ± 5.61 | −0.60 ± 5.04 | 0.72 ± 7.49 |
p | 0.112 | 0.003* | 0.005* |
New organ damage | | | |
Yes, n = 41 | −4.22 ± 5.35 | −3.30 ± 4.83 | −1.84 ± 7.09 |
No, n = 84 | −1.55 ± 5.53 | −0.84 ± 5.06 | −0.03 ± 7.39 |
p | 0.013* | 0.012* | 0.194 |
New renal damage | | | |
New renal damage, n = 10 | −8.03 ± 4.02 | −6.10 ± 3.90 | −5.16 ± 5.00 |
New other damage, n = 31 | −2.91 ± 5.17 | −2.34 ± 4.80 | −0.77 ± 7.39 |
p ** | 0.031* | 0.118 | 0.293 |
Hydroxychloroquine | | | |
Yes, n = 68 | −2.29 ± 5.25 | −1.88 ± 4.91 | −0.44 ± 7.11 |
No, n = 56 | −2.55 ± 6.05 | −1.31 ± 5.36 | −0.85 ± 7.61 |
p | 0.798 | 0.540 | 0.756 |
Immunosuppressants | | | |
Yes, n = 46 | −2.79 ± 6.55 | −2.59 ± 6.06 | −1.20 ± 8.32 |
No, n = 79 | −2.18 ± 4.99 | −1.06 ± 4.40 | −0.29 ± 6.69 |
p | 0.568 | 0.112 | 0.503 |
Oral glucocorticoids | | | |
Yes, n = 93 | −2.73 ± 5.90 | −2.13 ± 5.31 | −1.47 ± 7.55 |
No, n = 32 | −1.50 ± 4.61 | −0.21 ± 4.24 | 1.83 ± 6.03 |
p | 0.289 | 0.067 | 0.027* |
Daily oral glucocorticoids ≥ 7.5 mg for ≥ 3 mos | | |
Yes, n = 52 | −3.34 ± 5.51 | −3.35 ± 4.75 | −2.82 ± 7.09 |
No, n = 41 | −1.93 ± 6.35 | −0.54 ± 5.62 | 0.25 ± 7.86 |
p | 0.265 | 0.012* | 0.051 |
Antiosteoporosis therapies | | | |
Yes, n = 22 | 0.33 ± 5.67 | 1.93 ± 5.34 | 4.41 ± 7.51 |
No, n = 103 | −2.97 ± 5.43 | −2.37 ± 4.75 | −1.70 ± 6.84 |
p | 0.013* | < 0.0005* | < 0.0005* |